Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors. (April 2023)

• Record Type: Journal Article
• Authors: Spampinato, Sofia; Tanderup, Kari; Lindegaard, Jacob C.; Schmid, Maximilian P.; Sturdza, Alina; Segedin, Barbara; Jürgenliemk-Schulz, Ina M.; De Leeuw, Astrid; Bruheim, Kjersti; Mahantshetty, Umesh; Chargari, Cyrus; Rai, Bhavana; Cooper, Rachel; van der Steen-Banasik, Elzbieta; Sundset, Marit; Wiebe, Ericka; Villafranca, Elena; Van Limbergen, Erik; Pieters, Bradley R.; Tee Tan, Li; Lutgens, Ludy C.H.W.; Hoskin, Peter; Smet, Stéphanie; Pötter, Richard; Nout, Remi; Chopra, Supriya; Kirchheiner, Kathrin
• Is Part Of: Radiotherapy and oncology. Volume 181(2023)
• Publication Date: 2023-04
• Subjects: Locally advanced cervical cancer -- Quality of life -- Morbidity -- Patient reported outcome -- Clinical trial; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2023.109501
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: Impact of morbidity on quality of life (QOL) of cancer survivors depends on severity and persistence. Prospective data from EMBRACE-I allowed to assess the association for cervical cancer survivors. All persistent symptoms were significantly associated with QOL aspects, but with different magnitude. Role functioning and global health/general QOL were the most impaired aspects reported by patients. Persistent pain and fatigue were more detrimental compared to other organ-related symptoms. Abstract: Purpose: To quantify the association of persistent morbidity with different aspects of quality of life (QOL) in locally advanced cervical cancer (LACC) survivors. Material and methods: Longitudinal outcome from the EMBRACE-I study was evaluated. Patient-reported symptoms and QOL were prospectively scored (EORTC-C30/CX24) at baseline and regular follow-ups. Physician-assessed symptoms were also reported (CTCAEv.3). Persistent symptoms were defined if present in at least half of the follow-ups. QOL items were linearly transformed into a continuous scale. Linear mixed-effects models (LMM) were applied to evaluate and quantify the association of persistent symptoms with QOL. Overall QOL deterioration was evaluated by calculating the integral difference in QOL over time obtained with LMM for patients without and with persistent symptoms. Results: Out of 1416 patients enrolled, 741 with baseline and ≥ 3 late follow-ups were analyzed (median 59 months). Proportions of persistent EORTC symptoms ranged from 21.8 % to 64.9 % (bowel control and tiredness). For CTCAE the range was 11.3–28.6 % (limb edema and fatigue). Presence of any persistent symptom was associated with QOL, although with varying magnitude. Role functioning and Global health/QOL were the most impaired aspects. Fatigue and pain showed large differences, with reductions of around 20 % for most of the QOL aspects. Among organ-related symptoms, abdominal cramps showed the largest effect. Conclusion: Persistent symptoms are associated with QOL reductions in LACC survivors. Organ-related symptoms showed smaller differences than general symptoms such as fatigue and pain. In addition to optimizing treatment to minimize organ-related morbidity, effort should be directed towards a more comprehensive and targeted morbidity management.